Want to see AU:ACR full AI Analyst Report?
Acrux (ACR) AI Stock Analysis
Acrux
(ASX:ACR)
The score is constrained primarily by persistent losses, a thin and leveraged equity base, and limited valuation support. Improving revenue and cash generation provide meaningful positives, while mixed technical positioning and elevated RSI add moderate risk.
Acrux (ACR) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 40.14K
- Dividend Yield
- ―
- Average Volume (3M)
- 961.86K
- Price to Earnings (P/E)
- -7.1
- Beta (1Y)
- 0.56
- Revenue Growth
- 290.25%
- EPS Growth
- 92.05%
- Country
- Australia
- Employees
- 43
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Acrux Business Overview & Revenue Model
Company Description
Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international...
Acrux Financial Statement Overview
Summary
Revenue, gross profit, operating loss, net loss, and operating cash flow improved in 2026, but persistent losses, volatile results, and a stretched balance sheet with debt high relative to equity keep financial strength weak.
Income Statement
50NeutralBalance Sheet
30NegativeCash Flow
55Neutral| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.64M | 4.64M | 1.19M | 5.09M | 8.43M | 1.72M |
| Gross Profit | 4.21M | 4.21M | 1.19M | 1.13M | 1.95M | -4.65M |
| EBITDA | -1.70M | -1.70M | -5.17M | -8.06M | -2.79M | -12.29M |
| Net Income | -604.00K | -604.00K | -5.95M | -5.80M | -764.00K | -9.83M |
Balance Sheet | ||||||
| Total Assets | 6.82M | 6.82M | 7.22M | 8.96M | 14.30M | 15.27M |
| Cash, Cash Equivalents and Short-Term Investments | 1.71M | 1.71M | 863.00K | 2.94M | 6.23M | 5.83M |
| Total Debt | 2.52M | 2.52M | 3.63M | 3.70M | 2.35M | 2.08M |
| Total Liabilities | 5.36M | 5.36M | 6.20M | 5.69M | 5.60M | 6.18M |
| Stockholders Equity | 1.47M | 1.47M | 1.02M | 3.28M | 8.70M | 9.09M |
Cash Flow | ||||||
| Free Cash Flow | 1.23M | 1.02M | -5.48M | -4.58M | 584.00K | -9.28M |
| Operating Cash Flow | 1.23M | 1.02M | -5.47M | -4.30M | 703.00K | -8.82M |
| Investing Cash Flow | 0 | 0 | -5,000 | -276.00K | -119.00K | -465.00K |
| Financing Cash Flow | -388.00K | -178.00K | 3.39M | 1.29M | -183.00K | -155.00K |
Acrux Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ACR, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 45.52 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ACR.
Acrux Peers Comparison
Overall Rating
AU:CUV77Outperform- AU:ACR47Neutral
AU:BOT41Neutral
AU:SPL40Underperform
AU:CMB39Underperform
AU:TRP32Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:CUV | 77Outperform | AUD 355.93M | 11.15 | 13.00% | 0.71% | -1.05% | -6.74% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:ACR | 47Neutral | AUD 6.12M | -7.14 | -45.29% | ― | 290.25% | 92.05% |
| AU:BOT | 41Neutral | AUD 27.63M | -0.31 | -118.74% | ― | 499.47% | 31.20% |
| AU:SPL | 40Underperform | AUD 219.72M | -27.19 | -42.35% | ― | 145.32% | 25.75% |
| AU:CMB | 39Underperform | AUD 11.77M | -1.43 | -247.44% | ― | -4.24% | 33.39% |
| AU:TRP | 32Underperform | AUD 5.06M | -1.35 | -52.04% | ― | 32.22% | -26.53% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:ACR | Acrux Limited | 0.01 | -0.01 | -37.50% | |
| AU:CUV | Clinuvel Pharmaceuticals Limited | 7.08 | -3.63 | -33.86% | |
| AU:SPL | Starpharma Holdings Limited | 0.46 | 0.13 | 41.74% | |
| AU:TRP | Tissue Repair Ltd | 0.12 | -0.21 | -64.06% | |
| AU:CMB | Regeneus Ltd. | 0.36 | -0.14 | -28.00% | |
| AU:BOT | Botanix Pharmaceuticals Limited | 0.01 | -0.12 | -92.31% |
Acrux Corporate Events
Acrux Reports Expiry of 144,000 Performance Rights
Acrux Limited is an ASX-listed company, but the release does not provide details of its industry, products, services, or market focus. The company notified the market that 144,000 ACRAT performance rights ceased on November 4, 2026, after expiring wi...
Acrux Seeks ASX Quotation of 100,000 Shares
Acrux Limited applied for quotation of 100,000 fully paid ordinary shares on the ASX, with an issue date of November 4, 2026. The shares were previously issued under an employee incentive scheme and became, or were about to become, transferable after...
Acrux Sets November AGM to Vote on Board, Remuneration and Capital Measures
Acrux Ltd has called its 2026 Annual General Meeting for 24 November in Melbourne, inviting shareholders to attend in person or lodge proxy votes in advance, with meeting materials available via the company’s investor website. The AGM will cons...
Acrux Seeks ASX Quotation for 500,000 Employee Incentive Shares
Acrux Limited, an Australian Securities Exchange-listed pharmaceutical company, issues ordinary fully paid shares under the code ACR as part of its presence in the healthcare sector. The business relies on capital markets access and structured share...
Acrux Secures FDA Pathway and Posts Positive Quarterly Cash Flow
Acrux reported positive net operating cash of $0.266 million for the September quarter, supported by the receipt of a $1.977 million Research and Development Tax Incentive rebate and steady profit share and royalty income from its U.S. topical generi...
FDA Clears Acrux’s Path to Phase III and Potential Exclusivity for Female Testosterone Spray
Acrux Limited, an Australian pharmaceutical developer of transdermal drug delivery products, is advancing a metered-dose testosterone spray for postmenopausal women with hypoactive sexual desire disorder. The company is targeting the U.S. market with...
Acrux to Brief Investors on Female Testosterone MDTS and FDA Feedback
Acrux has scheduled a live investor webinar on 12 October 2026 to brief shareholders on its Female Testosterone Metered Dose Transdermal System (MDTS). The session will feature CEO John Warmbrunn outlining recent feedback from the U.S. Food and Drug...
Acrux Sets November AGM and Opens Director Nominations
Acrux Limited has scheduled its next Annual General Meeting for 24 November 2026 at the offices of Pitcher Partners in Docklands, Melbourne, where the election of directors will be a key item of business. The company has opened the nomination process...
Acrux Seeks ASX Quotation for 4.1 Million Employee Scheme Shares
Acrux Limited has applied for quotation on the ASX of 4,109,653 ordinary fully paid shares, with an issue date of 14 September 2026. These securities were previously issued under an employee incentive scheme and are now having their transfer restrict...
Acrux Director Boosts Equity Stake via Loan-Funded Share Issue
Acrux Limited has reported a change in director Geoffrey Brooke’s interests, reflecting an issue of 2,400,000 new ordinary shares to him supported by a limited recourse, interest-free loan. Following the transaction, Brooke’s direct and i...
Acrux Discloses New Equity Award to Director Under Loan Structure
Acrux Ltd has disclosed a change in director John Warmbrunn’s interests in company securities, in line with ASX listing rules and Australian corporate law. The notice underscores the company’s adherence to governance and reporting standar...
Acrux Boosts Director Equity via Loan-Funded Share Issue
Acrux Ltd has disclosed a change in director Tim Oldham’s interests in the company’s securities, reflecting adjustments to his direct and indirect holdings. The notice details his existing stake through related entities and personal holdi...
Acrux Boosts Director Equity Stake Through Loan-Supported Share Issue
Acrux Ltd has disclosed a change in director interests, detailing an update to the shareholdings of board member Don Brumley. The company, an ASX-listed pharmaceutical developer specialising in drug delivery technologies, continues to use equity-base...
Acrux Seeks ASX Quotation for Employee Incentive Shares
Acrux Limited has applied for quotation on the ASX of 716,679 ordinary fully paid shares, with an issue date of 3 September 2026. The shares relate to securities previously issued under an employee incentive scheme, for which transfer restrictions ha...
Acrux Seeks ASX Quotation for 15.75 Million New Shares
Acrux Limited, an ASX-listed pharmaceutical developer, issues ordinary fully paid shares as part of its capital structure and relies on employee incentive schemes to support talent retention and align staff with shareholder outcomes. The company̵...
Acrux Updates Market With 2026 Governance and Compliance Filings
Acrux Limited has released its Appendix 4G and Corporate Governance Statement for the financial year ended 30 June 2026, as authorised by its board. The disclosures outline the company’s governance framework, compliance with ASX principles and...
Acrux to Brief Investors on Women’s Health Hormone Therapy Strategy
Acrux Limited will host an investor webinar on 17 August 2026 to update shareholders and the market on its progress in executing a development strategy centred on women’s health and hormone replacement therapies. CEO and Managing Director John...
Acrux Seeks ASX Quotation for 200,000 Employee Scheme Shares
Acrux Limited has applied to the ASX for quotation of 200,000 ordinary fully paid shares, with the securities scheduled for issue on 13 August 2026. The new quoted shares arise from securities previously issued under an employee incentive scheme, for...
Acrux Reports Lapse of 110,000 Performance Rights
Acrux Limited has notified the market of a change to its issued capital following the lapse of 110,000 performance rights. The rights ceased on 13 August 2026 after the conditions attached to these securities were not met or became incapable of being...
Acrux Highlights Female Testosterone Strategy at Bioshares Biotech Summit
Acrux Limited announced that CEO and Managing Director John Warmbrunn is presenting at Bioshares’ 20th Biotech Summit. The investor presentation, which accompanies the announcement, places a clear emphasis on female testosterone, underscoring A...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 13, 2026